JDQ443,tislelizumab
Novartis,Beigene
['kontrast-01', 'jdq443', 'sclc', 'lcsm,(-blcsm)', 'solid tumor', 'nsclc']
kontrast-01 shows safety and preliminar efficacy of jdq443 monotherapy in kras mutant nsclc (and other solid tumors). #asco23 #lcsm 
Husband, Father. Medical Oncologist and Researcher focused in Thoracic Oncology.  Views are my own. Member of @latenightonc - the best podcast in oncology!